Looking for source of study posted here

alizarin

I'm looking for any info that can lead me to the source of this study:

www.breastcancer.org/symptoms/new_research/20090710.jsp

"Women Treated for Hormone-Receptor-Negative Cancers More Likely to be Diagnosed with New Cancer in Other Breast"

Moderators

Hi Alizarin,

This Breastcancer.org Research News article was a commentary on a Medpage article (original article in text below). The original journal abstract on which that article was based can be found here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720990/

Receptor Status Drives Contralateral Breast Cancer Risk

HOUSTON, July 10 (MedPage Today) -- Women with hormone
receptor-negative breast cancer had more than a tripling of risk of
contralateral breast cancer compared with women who had
receptor-positive primary tumors, a study of almost 5,000 women
showed.

Moreover, survivors of receptor-negative breast cancer had a 10-fold
greater risk of developing a receptor-negative second primary tumor
compared with the general population, Christina A. Clarke, PhD, of the
Northern California Cancer Center in Fremont, and colleagues reported
in the July 9 issue of the Journal of the National Cancer Institute.

The findings have potentially major implications for follow-up of
breast cancer survivors.

"Currently, guidelines of the American Cancer Society recommend
intensive breast screening with yearly MRI for women at increased risk
of developing breast cancer," the authors said.

"In this context and in light of reports that standard mammography has
low sensitivity for detecting HR-negative tumors, our findings, if
confirmed, suggest that women diagnosed with an HR-negative breast
cancer would benefit from MRI-based breast screening."

Almost one in 25 breast cancer survivors will develop a second primary
breast cancer within six months of the initial diagnosis. Aside from a
link to a strong family history of breast cancer, little is known
about patterns of second primary breast cancer, particularly within
the context of breast cancer heterogeneity.

In an effort to increase the knowledge base about second primary
breast cancer, Dr. Clarke and colleagues turned to the NCI's
Surveillance, Epidemiology, and End Results (SEER) database.

They identified a population-based cohort of 4,927 women with an
initial diagnosis of breast cancer and then followed the patients'
clinical course to ascertain occurrence of second primary breast
tumors.

The study population comprised 3,701 who had a first hormone
receptor-positive tumor and 1,226 who had a receptor-negative first
primary.

Women with a receptor-positive initial cancer had a twofold greater
risk of contralateral primary breast cancer compared with the general
population, reflected in a standardized incidence ratio (SIR) of 2.22.

Women whose first primary was hormone receptor-negative had more than
threefold greater risk of a second primary compared with patients
whose initial cancer was receptor-positive (SIR 3.57, 95% CI 3.38 to
3.78).

A receptor-negative first primary tumor substantially increased the
risk of a second receptor-negative breast cancer (SIR 9.81, 95% CI
9.00 to 10.7) compared with general population. The risk of a
receptor-positive contralateral breast cancer was approximately
twofold greater (SIR 1.94, 95% CI 1.77 to 2.13).

By contrast, for those with receptor-positive first tumors, the risks
for a hormone receptor-positive or -negative second tumor were
similar.

Diagnosis of hormone receptor-negative breast cancer before age 30 had
a dramatic effect on a woman's risk of receptor-negative contralateral
primary breast cancer (SIR 169, 95% CI 106 to 256).

The risk of any contralateral breast cancer, irrespective of the
primary tumor's receptor status, was greater in non-Hispanic blacks,
Hispanics, and Asians or Pacific Islanders compared with non-Hispanic
whites.

The study had limitations including lack of data on HER2/neu status,
risk factors for breast cancer, family history, genetic mutations, and
treatments for the first tumor, especially tamoxifen.

The study was supported by National Cancer Institute's Surveillance,
Epidemiology, and End Results Program under contract N01-PC-35136 with
the Northern California Cancer Center.

The authors reported no financial disclosures.